Performance of Automated Scoring of ER, PR, HER2, CK5/6 and EGFR in Breast Cancer Tissue Microarrays in the Breast Cancer Association Consortium

The Clinical Journal of Pathology
doi 10.1002/cjp2.00003
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

EGFR and HER2 Signaling in Breast Cancer Brain Metastasis

Frontiers in Bioscience - Elite
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2016English

Pmd31 - The Concordance and Budget Impact of Multiple Er, Pr and Her2 Determinations in Dutch Breast Cancer Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Breast Cancer Subtypes Among Iraqi Patients: Identified by Their ER, PR and HER2 Status

Journal of the faculty of medicine baghdad
2017English

FGF Receptor Genes and Breast Cancer Susceptibility: Results From the Breast Cancer Association Consortium

British Journal of Cancer
Cancer ResearchOncology
2014English

Is There a Role of Breast Pathologist in Diagnostic Challenges of Discordances in ER, PR, and HER2 Between Primary Breast Cancer and Brain Metastasis?

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2018English

CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2 + Breast Cancer

Cancer Cell
Cancer ResearchOncologyCell Biology
2016English

Prognostic and Predictive Values of EGFR Overexpression and EGFR Copy Number Alteration in HER2-positive Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
2014English

Treating ER+ Breast Cancer With CDK4/6 Inhibitors

Cancer Discovery
Oncology
2017English

Results of 1-Year Diet and Exercise Interventions for ER+/PR+-/HER2- Breast Cancer Patients Correlated With Treatment Type

Chirurgia (Bucharest, Romania : 1990)
Surgery
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy